Clinical trial
An Open Label, Single-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effect of LY3981314 in Patients With Autoimmune Hepatitis
NCT07928219 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Single-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effect of LY3981314 in Patients With Autoimmune Hepatitis
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- June 30, 2028
- Enrollment
- 12 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
hepatitis, hepatitis autoimmune disease
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,100 more trials See the organization page
Similar trials
Same condition (Hepatitis) and phase, most recent start first.
+19 more trials See the condition page